Vonoprazan not checked

Phathom Pharmaceuticals, Inc.

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
2 active
14 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Symptomatic Non-erosive Gastroesophageal Reflux Disease, Eosinophilic Esophagitis
Main trialPhase 3
“The main objective is to assess the efficacy of vonoprazan (10 mg as needed) compared to placebo (as needed) in relief of episodic heartburn at 2 hours that is sustained for 24 hours over 12 weeks of treatment in participants with non-erosive gastroesophageal reflux disease (GERD).”In the company’s words, NCT07752407 on ClinicalTrials.gov

Other drugs for Symptomatic Non-erosive Gastroesophageal Reflux Disease

All 7 drugs for Symptomatic Non-erosive Gastroesophageal Reflux Disease

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials14

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 20 Oct 2027 A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks
Phase 2Active, not recruiting 11 Sep 2026 A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
Phase 3Completed 10 Mar 2021 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection
Phase 3Completed 29 Jul 2021 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis
Phase 3Completed 21 Nov 2022 A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
Phase 2Completed 16 Dec 2021 A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
Phase 1Completed 13 Nov 2020 Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants
Phase 1Withdrawn 7 Feb 2021 Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants
Phase 1Completed 12 Jun 2021 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants
Phase 1Completed 1 Jul 2022 A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants
Phase 1Completed 30 May 2023 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease
Phase 1Completed 16 Apr 2024 A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease
Phase 1Completed 13 Sep 2024 A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
Phase 1Completed 5 Apr 2025 A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Vonoprazan

Following is part of Solo: you see every change to Vonoprazan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in